固摄方联合吉非替尼抑制A549小鼠肺癌组织机制研究  

Study on Astringent Decoction combined with Gefitinib Inhibition Lung Cancer Tissue Mechanism of A549 Mouse

作　　者：黄佳琴[1] 李忠[1] 

机构地区：[1]北京中医药大学东直门医院,北京100700

出　　处：《中医学报》2014年第4期476-478,共3页Acta Chinese Medicine

基　　金：北京中医药大学自主研究课题(编号:2009JYB22-JS080)

摘　　要：目的：确定固摄方协同吉非替尼是否具有协同抑制实验性肿瘤生长效应，以评估临床应用前景．方法：用固摄方、吉非替尼分别及联合作用于4—5周龄A549小鼠，采用流式细胞术、免疫组织化学染色观察各组BCL-2、GST、HER-2、Top-2、CD31和TIMP-2水平。检测各组肿瘤质量、体积，计算抑瘤率。结果：①模型对照组的BCL-2和TIMP-2的表达最弱，与固摄方加吉非替尼1组比较，差异有统计学意义（P〈0．05）。②模型对照组的CD31表达最强，与其他各组比较，差异均有统计学意义（P〈0．05）。③Top-2：固摄方加吉非替尼2组表达最强，模型对照组表达最弱，两组比较，差异有统计学意义（P〈0．05）。④各组小鼠的抑瘤率不同，固摄方加吉非替尼1组效果最好。结论：固摄方联合吉非替尼对抑制A549小鼠肺癌组织可能具有协同效应。Objective： To determine whether Astringent Decoction collaborative Gefitinib has synergies inhihiting eltect in experimental tumor growth,and to evaluate the possibility of clinical prospect. Methods： With Astringent Decoction and Gefitinib respectively and combined effects at four to five weeks old BALB/C nude mice with lung cancer, using flow cytometry and immunohistochemical staining to observe BCL-2, GST, HER-2,Top-2, CD31,TIMP-2 levels in each group. Testing each groups of tumor weight, volume, and calcula- tion the tumor inhibitory rate. Results ： @The BCL-2,TIMP-2 expression in model control group in the weakest, and had a statistical difference combined with Astringent Decoction and Gefitinib 1 group （P 〈 0.05）. @Model control group had the strongest expression of CD31, and was statistically different with the other groups（ P 〈 0.05 ）. @Top-2 express strongest in Gefitinib collaborative Astringent Decoction 2 group, and model control group was the weakest, both of them had difference（P 〈 0.05）. @The inhibition rate of mice in each group was different,Gefitinib combined with Astringent Decoction 1 group was the best. Conclusion： Astringent Decoction com- bined with Gefitinib may have a synergistic effect to inhibit A549 lung cancer tissue in mice.

关 键 词：肺癌 固摄方 吉非替尼 A549小鼠 肺癌组织 

分 类 号：R273.342[医药卫生—中西医结合]